The Role of Stem Cells in Retinal Conditions

Stem cells have emerged as a promising therapeutic avenue for a range of retinal conditions, offering hope for diseases previously deemed untreatable. Retinal conditions, including age-related macular degeneration (AMD), retinitis pigmentosa and diabetic retinopathy, lead to significant vision loss and affect millions globally. The ability of stem cells to differentiate into retinal cells presents a groundbreaking opportunity for regenerative medicine, aiming to restore or preserve vision.

Despite significant advances in gene therapy for the treatment of primarily inherited retinal diseases (IRDs) and the approval of the first gene therapy AAV8 subretinal vector Luxturna (Voretigene Neparvovec), there are significant limitations in delivery (subretinal) and outcomes (functional improvements). Stem cell treatments could potentially address these limitations across a larger spectrum of retinal conditions.

This Special Issue explores the latest advancements in this field. It encompasses various types of stem cells, such as embryonic stem cells, induced pluripotent stem cells (iPSCs) and adult stem cells, each offering unique potentials and challenges. The Special Issue examines the mechanisms of retinal cell differentiation, the integration of these cells into existing retinal structures and the functional restoration of vision.

The importance of this research lies in its potential to transform the landscape of retinal disease treatment. Stem cell therapy promises not only to halt the progression of retinal degeneration, but also regenerate damaged tissues, offering a beacon of hope for patients. This Special Issue highlights preclinical studies, clinical trials and the translational journey from bench to bedside, underscoring the challenges and ethical considerations in stem cell research.

The goal of this Special Issue is to provide a comprehensive overview of current research, stimulate discussion on future directions and encourage collaboration across disciplines. By bridging the gaps between basic science, clinical application and bioethics, it aims to accelerate the development of effective stem cell-based therapies for retinal conditions.

Dr. Georgios Panos
Dr. Theo Empeslidis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Stem cells
• Retinal conditions
• Regenerative medicine
• Age-related macular degeneration (AMD)
• Retinitis pigmentosa
• Diabetic retinopathy
• Induced pluripotent stem cells (iPSCs)
• Cell differentiation
• Vision restoration
• Clinical trials